Physician profile
Won S Chang
NPI 1992787618
$1,893.73
in general payments reported to CMS, 2019-2025
21 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.17 · 2021: $133 · 2022: $148 · 2023: $280 · 2024: $1,048 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.46 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $629.69 | 2019-2024 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $519.00 | 2021-2024 | Opdivo |
| Gilead Sciences, INC. | $119.70 | 2025 | Trodelvy |
| Abbvie INC. | $119.70 | 2024 | |
| Janssen Biotech, INC. | $56.80 | 2024 | Darzalex |
| Pfizer INC. | $54.64 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $42.53 | 2024 | Libtayo |
| Morphosys, US INC. | $41.67 | 2023 | Monjuvi |
| Foundation Medicine, INC. | $35.54 | 2022 | |
| Teleflex LLC | $31.86 | 2025 | Barrigel |
| Takeda Pharmaceuticals U.S.A., INC. | $26.17 | 2023 | Ninlaro |
| Lilly USA, LLC | $24.94 | 2024 | Jaypirca, Retevmo, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $24.48 | 2024 | |
| Eisai INC. | $24.08 | 2023 | |
| Novartis Pharmaceuticals Corporation | $24.06 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.59 | 2023 | Enhertu |
| Merck Sharp & Dohme LLC | $22.02 | 2024 | Keytruda |
| Glaxosmithkline, LLC. | $21.12 | 2024 | Zejula, Jemperli |
| Alexion Pharmaceuticals, INC. | $19.00 | 2025 | Ultomiris |
| Seagen INC. | $17.09 | 2023 | Adcetris |
| Genentech USA, INC. | $17.05 | 2024 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Won Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.